Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Notes European Expansion, IP Portfolio Updates, to Participate in Neuropsychiatry Virtual Summit

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is increasing its focus and research activities in Europe. The company announced that it is working with several academic and clinical research organizations as part of those efforts, which include the transfer of its intellectual property assets to its recently formed wholly owned Ireland subsidiary. According to the announcement, Cybin will also continue building its IP portfolio of novel psychedelic compounds, delivery platforms and methods of use in psychiatric indications. The company noted that its growing portfolio of intellectual property includes 12 patent filings and four active drug programs featuring Cybin’s proprietary novel psychedelic compounds and focusing on three mental health indications: major depressive disorder, alcohol use disorder and anxiety disorders. In addition, the company has most recently filed an international patent application aimed at potentially obtaining patent coverage in 153 countries; the announcement also noted that the company has completed 51 preclinical studies designed to support progression of its novel molecules into clinical studies in early 2022.

In addition, Cybin has announced that its CEO Doug Drysdale will participate in a panel discussion at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13, 2021. The panel, “Emerging Psychedelic Therapies in the Field of Neuropsychiatry,” is slated to begin at 4:15 p.m. Eastern Time on the day of the event.

To view the full press releases, visit https://ibn.fm/MjD9h and https://ibn.fm/M79Jl

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in Cybin Inc. CLXPF, MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.